Learn more about Indica Labs’ novel CE-IVD certified deep learning clinical workflow for prostate cancer grading.
Novel CE-IVD clinical workflow for analysis of prostate cancer core needle biopsies Read More »
Learn more about Lung Macrodissect AI, an AI-based tool for tumor content quantification and ROI selection guidance.
Learn how Kaiser Permanente deployed Breast IHC AI as a laboratory developed test.
Validation and Clinical Implementation of Breast IHC AI Read More »
Check out our HALO Prostate AI brochure to learn more about our CE-IVD certified deep learning-based screening tool designed to assist pathologists in the identification and grading of prostate cancer in core needle biopsies.
HALO Prostate AI Brochure Read More »
Learn how this AI-powered tool standardized breast cancer biomarker quantification to include HER2 low and ultralow.
Breast IHC AI Brochure Read More »
Read about the development and validation of an AI-based PD-L1 scoring algorithm for HALO AP®.
Learn more about the development and validation of an AI-based molecular pathology algorithm for estimating tumour cells in lung adenocarcinoma.
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »
